Press release

Dr. Andreas Hartlep is the new Chief Technology Officer at cerbomed

Erlangen, May 28th, 2009. cerbomed gmbh, a start-up company in the area of neurostimulation, announced

today that Dr. Andreas Hartlep will take on the position as Chief Technology Officer (CTO).

Dr. Andreas Hartlep brings more than 10 years experience from different management positions in research

and development, as well as clinical operations associated with medical engineering, to this leading role. Be-

fore his last position as an Executive Director of R&D at Prosurgics, a London-based start-up in image controlled

robotics, he was the Director of Clinical Operations at Timaq Medical Imaging, an innovative Swiss consultancy

specializing in imaging solutions for pharmaceutical and medical-technology companies. Before this, Dr. Hart-

lep worked for more than seven years as Research Director at BrainLab, where among other duties, he was

responsible for setting up the unit for image-controlled interstitial infusion.

"In Dr. Andreas Hartlep, we have got ourselves an outstanding technology manager with whom we will succeed

to guide our innovation in transcutaneous vagus nerve stimulation (t-VNS®) to market maturity," says Christoph

Bally, Chief Executive Officer (CEO) of the company. He ideally complements the existing business management

team of Christoph Bally and the two company founders Dr. Stefan Dietrich and Timo Freitag.

Dr. Andreas Hartlep studied at the universities of Kiel and Heidelberg and graduated in physics and medical

physics. He got his Ph.D. (Dr.rer. nat.) at the German cancer research centre (DKFZ) in Heidelberg. After his

interdisciplinary professional experience in the areas of medical engineering and neuroscience, the 43-year-old

inhabitant of Munich is already looking forward to his new tasks: "I see a huge potential in cerbomed’s innova-

tion, which can lower the suffering of patients with neuropsychiatric illnesses."

About cerbomed:

cerbomed is a young, medical device company focusing on the research, development and manufacturing of

innovative technologies and products in the area of neurostimulation. Its major proprietary procedure, tran-

scutaneous vagus nerve stimulation (t-VNS®), will offer a new, alternative treatment for various neuropsychia-

tric disorders with clinical benefit and improved quality of life at a superior cost benefit ratio.

Since its foundation in December 2005, cerbomed has received many innovation and new enterprise prices

(including university- and chamber of commerce new enterprise awards), and was among the federal winners

of the German new enterprise prize in 2006.

Contact

cerbomed gmbh

Dr. Martin Hyca

Marketing Director

Henkestrasse 91

91052 Erlangen

Phone: +49 (0) 9131 9202 760

Mail: martin.hyca@cerbomed.com